Related references
Note: Only part of the references are listed.2019 Update to: Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
John B. Buse et al.
DIABETES CARE (2020)
Linagliptin and cardiorenal outcomes in Asians with type 2 diabetes mellitus and established cardiovascular and/or kidney disease: subgroup analysis of the randomized CARMELINA® trial
Nobuya Inagaki et al.
DIABETOLOGY INTERNATIONAL (2020)
Linagliptin as add-on to empagliflozin in a fixed-dose combination in Japanese patients with type 2 diabetes: Glycaemic efficacy and safety profile in a two-part, randomized, placebo-controlled trial
Kohei Kaku et al.
DIABETES OBESITY & METABOLISM (2019)
Effects of canagliflozin on amputation risk in type 2 diabetes: the CANVAS Program
David R. Matthews et al.
DIABETOLOGIA (2019)
Hypoglycaemia, cardiovascular disease, and mortality in diabetes: epidemiology, pathogenesis, and management
Stephanie A. Amiel et al.
LANCET DIABETES & ENDOCRINOLOGY (2019)
An update on the safety of SGLT2 inhibitors
Andre J. Scheen
EXPERT OPINION ON DRUG SAFETY (2019)
Hypoglycemia in diabetes: The dark side of diabetes treatment. A patient-centered review
Brianna Johnson-Rabbett et al.
JOURNAL OF DIABETES (2019)
Safety and tolerability of empagliflozin in East Asian patients with type 2 diabetes: Pooled analysis of phase I-III clinical trials
Daisuke Yabe et al.
JOURNAL OF DIABETES INVESTIGATION (2019)
DPP-4 Inhibition and the Path to Clinical Proof
Bo Ahren
FRONTIERS IN ENDOCRINOLOGY (2019)
Impact of severe hypoglycaemia on psychological outcomes in adults with Type 2 diabetes: a systematic review
C. Hendrieckx et al.
DIABETIC MEDICINE (2019)
Effect of Linagliptin vs Glimepiride on Major Adverse Cardiovascular Outcomes in Patients With Type 2 Diabetes: The CAROLINA Randomized Clinical Trial
Julio Rosenstock et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2019)
Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk The CARMELINA Randomized Clinical Trial
Julio Rosenstock et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2019)
Safety and Tolerability of Combinations of Empagliflozin and Linagliptin in Patients with Type 2 Diabetes: Pooled Data from Two Randomized Controlled Trials
Ralph A. DeFronzo et al.
ADVANCES IN THERAPY (2018)
Empagliflozin as add-on to linagliptin in a fixed-dose combination in Japanese patients with type 2 diabetes: Glycaemic efficacy and safety profile in a 52-week, randomized, placebo-controlled trial
Ryuzo Kawamori et al.
DIABETES OBESITY & METABOLISM (2018)
Diabetes and chronic kidney disease: an increasingly common multi-morbid disease in need of a paradigm shift in care
P. H. Winocour
DIABETIC MEDICINE (2018)
Japanese Clinical Practice Guideline for Diabetes 2016
Masakazu Haneda et al.
JOURNAL OF DIABETES INVESTIGATION (2018)
Empagliflozin Induces Transient Diuresis Without Changing Long-Term Overall Fluid Balance in Japanese Patients With Type 2 Diabetes
Atsutaka Yasui et al.
DIABETES THERAPY (2018)
Empagliflozin Induces Transient Diuresis Without Changing Long-Term Overall Fluid Balance in Japanese Patients With Type 2 Diabetes
Atsutaka Yasui et al.
DIABETES THERAPY (2018)
Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
Melanie J. Davies et al.
DIABETES CARE (2018)
How Does Empagliflozin Reduce Cardiovascular Mortality? Insights From a Mediation Analysis of the EMPA-REG OUTCOME Trial
Silvio E. Inzucchi et al.
DIABETES CARE (2018)
Empagliflozin and Assessment of Lower-Limb Amputations in the EMPA-REG OUTCOME Trial
Silvio E. Inzucchi et al.
DIABETES CARE (2018)
Empagliflozin as Add-on Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Linagliptin and Metformin: A 24-Week Randomized, Double-Blind, Parallel-Group Trial
Eirik Softeland et al.
DIABETES CARE (2017)
Linagliptin as add-on to empagliflozin and metformin in patients with type 2 diabetes: Two 24-week randomized, double-blind, double-dummy, parallel-group trials
Francisco J. Tinahones et al.
DIABETES OBESITY & METABOLISM (2017)
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Bruce Neal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial
David Z. I. Cherney et al.
LANCET DIABETES & ENDOCRINOLOGY (2017)
Safety, Efficacy, and Bioavailability of Fixed-Dose Combinations in Type 2 Diabetes Mellitus: A Systematic Updated Review
Thangavel Mahalingam Vijayakumar et al.
CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL (2017)
Safety and Tolerability of Empagliflozin in Patients with Type 2 Diabetes: Pooled Analysis of Phase I-III Clinical Trials
Sven Kohler et al.
ADVANCES IN THERAPY (2017)
Empagliflozin and Cardiovascular Outcomes in Asian Patients With Type 2 Diabetes and Established Cardiovascular Disease - Results From EMPA-REG OUTCOME®
Kohei Kaku et al.
CIRCULATION JOURNAL (2017)
Changing epidemiology of type 2 diabetes mellitus and associated chronic kidney disease
Merlin C. Thomas et al.
NATURE REVIEWS NEPHROLOGY (2016)
Pharmacodynamic Effects of Single and Multiple Doses of Empagliflozin in Patients With Type 2 Diabetes
Tim Heise et al.
CLINICAL THERAPEUTICS (2016)
DPP-4 inhibitor plus SGLT-2 inhibitor as combination therapy for type 2 diabetes: from rationale to clinical aspects
Andre J. Scheen
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2016)
An update on DPP-4 inhibitors in the management of type 2 diabetes
Avivit Cahn et al.
EXPERT OPINION ON EMERGING DRUGS (2016)
Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
Christoph Wanner et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Probing SGLT2 as a therapeutic target for diabetes: Basic physiology and consequences
Linda A. Gallo et al.
DIABETES & VASCULAR DISEASE RESEARCH (2015)
Initial Combination of Empagliflozin and Linagliptin in Subjects With Type 2 Diabetes
Andrew Lewin et al.
DIABETES CARE (2015)
Combination of Empagliflozin and Linagliptin as Second-Line Therapy in Subjects With Type 2 Diabetes Inadequately Controlled on Metformin
Ralph A. DeFronzo et al.
DIABETES CARE (2015)
Potential for combination of dipeptidyl peptidase-4 inhibitors and sodium-glucose co-transporter-2 inhibitors for the treatment of type 2 diabetes
M. D. Sharma
DIABETES OBESITY & METABOLISM (2015)
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Bernard Zinman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Potential for dipeptidyl peptidase-4 inhibitor and sodium glucose cotransporter 2 inhibitor single-pill combinations
Devada Singh-Franco
EXPERT REVIEW OF ENDOCRINOLOGY & METABOLISM (2015)
Safety and Tolerability of Linagliptin in Patients With Type 2 Diabetes: A Comprehensive Pooled Analysis of 22 Placebo-controlled Studies
Michael Lehrke et al.
CLINICAL THERAPEUTICS (2014)
Hypoglycaemia in diabetes mellitus: epidemiology and clinical implications
Brian M. Frier
NATURE REVIEWS ENDOCRINOLOGY (2014)
Hypoglycemia and Diabetes: A Report of a Workgroup of the American Diabetes Association and The Endocrine Society
Elizabeth R. Seaquist et al.
DIABETES CARE (2013)
Avoiding hypoglycemia: a key to success for glucose-lowering therapy in type 2 diabetes
Bo Ahren
VASCULAR HEALTH AND RISK MANAGEMENT (2013)
Fixed-Dose Combinations for Treatment of Type 2 Diabetes Mellitus
Lawrence Blonde et al.
ADVANCES IN THERAPY (2012)
A systematic review of adherence, treatment satisfaction and costs, in fixed-dose combination regimens in type 2 diabetes
Valerie Hutchins et al.
CURRENT MEDICAL RESEARCH AND OPINION (2011)
Patient-reported outcomes in a survey of patients treated with oral antihyperglycaemic medications: associations with hypoglycaemia and weight gain
E. Marrett et al.
DIABETES OBESITY & METABOLISM (2009)
Share Paper
